NCT01123525

Adenosine Cardioplegia; Improved Cardioprotection?

Adenosine Instead of Supranormal Potassium in Crystalloid Cardioplegia, a Randomized Clinical Study

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: University Hospital of North Norway · Academic / Other
• Sex: All
• Age: 40 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

60 elective patients for CABG will be included to receive either standard hyperkalemic cardioplegia (St.Thomas Hospital Solution No I) or cardioplegia where supranormal potassium is replaced with 1.2 mM adenosine. Hypothesis as follows: 1. Adenosine instead of supranormal potassium in the cardioplegic solution give satisfactory cardiac arrest. 2. Adenosine instead of supranormal potassium in the cardioplegic solution gives equal cardioprotection. The patients will be followed with PiCCO-catheter to monitor cardiac function and repetitive blood samples to measure release of cardiac enzymes.

Conditions

• Angina Pectoris

Interventions

Type	Name	Description
DRUG	Adenosine	1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution

Timeline

• Start date: 2010-04-01
• Primary completion: 2011-04-01
• Completion: 2011-09-01
• First posted: 2010-05-14
• Last updated: 2011-09-30

Locations

1 site across 1 country: Norway